In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 1047-1051

  Wareham, D W ^a,b   Gordon, N C ^a   Hornsey, M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

Antimicrobial synergy; Glycopeptides; Polymyxins

Indexed keywords

COLISTIN; TEICOPLANIN;

ACINETOBACTER BAUMANNII; AGAR DILUTION; ANTIMICROBIAL ACTIVITY; ARTICLE; ASSAY; BACTERIAL STRAIN; IN VITRO STUDY; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; TIME KILL ASSAY; UNITED KINGDOM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GREAT BRITAIN; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; TEICOPLANIN;

EID: 79954596970     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr069     Document Type: Article

References (22)

1. Hornsey M, Ellington MJ, Doumith M et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 1589-93.
2. Park YK, Jung SI, Park KH et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009; 64: 43-51.
3. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrugresistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775-80.
4. FDA. FDA Drug Safety Communication: Increased Risk of Death with Tygacil (Tigecycline) Compared to Other Antibiotics Used to Treat Similar Infections. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (20 December 2010, date last accessed).
5. Lim LM, Ly N, Anderson D et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010; 30: 1279-91.
6. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35: 219-26.
7. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 5316-22.
8. Deryke CA, Crawford AJ, Uddin N et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54: 4503-5.
9. Wong-Beringer A, Joo J, Tse E et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37: 95-101.
10. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53: 4069-79.
11. Cavalcanti AB, Goncalves AR, Almeida CS et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; issue 6: CD007022.
12. Turton JF, Matos J, Kaufmann ME et al. Variable number tandem repeat loci providing discrimination within widespread genotypes of Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 2009; 28: 499-507.
13. Turton JF, Kaufmann ME, Gill MJ et al. Comparison of Acinetobacter baumannii isolates from the United Kingdom and the United States that were associated with repatriated casualties of the Iraq conflict. J Clin Microbiol 2006; 44: 2630-4.
14. Milne KE, Gould IM. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 2010; 65: 82-90.
15. Wareham DW, Bean DC. In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 825-6.
16. BSAC. BSAC Methods for Antimicrobial Susceptibility Testing, Version 9.1 March 2010. http://www.bsac.org.uk/Resources/BSAC/Version_9.1_March_2010_final.pdf (20 December 2010, date last accessed).
17. Markou NS, Markantonis L, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-51.
18. Brink AJ, Richards GA, Cummins RR et al. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Int J Antimicrob Agents 2008; 32: 455-8.
19. Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 2006; 5: 10.
20. Pankey GA, Ashcraft DS. In vitro synergy of ciprofloxacin and gatifloxacin against ciprofloxacin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 2959-64.
21. Greenberg RN. Treatment of bone, joint, and vascular-accessassociated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392-7.
22. Vaara M. Polymyxins and their novel derivatives. Curr Opinion Microbiol 2010; 13: 574-81.